TiumBio Co., Ltd.

A321550

KR7321550006

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-05-30 pm EDT			5-day change	1st Jan Change
6,770 ^KRW	+2.73%		-4.38%	-30.71%

Jun. 01	Tiumbio Co., Ltd. Presents Phase 1B Interim Results for Tu2218 in Combination with Pembrolizumab At Asco 2024 Annual Meeting	CI
May. 08	TiumBio Co., Ltd. Announces Positive Topline Data from Phase 2A Trial of Merigolix in Patients with Moderate to Severe Endometriosis-Associated Pain	CI

Protium Science announced that it has received KRW 6 billion in funding from TiumBio Co., Ltd.

September 26, 2021

On September 27, 2021, Protium Science closed the transaction.

Latest news about TiumBio Co., Ltd.

Tiumbio Co., Ltd. Presents Phase 1B Interim Results for Tu2218 in Combination with Pembrolizumab At Asco 2024 Annual Meeting	Jun. 01	CI
TiumBio Co., Ltd. Announces Positive Topline Data from Phase 2A Trial of Merigolix in Patients with Moderate to Severe Endometriosis-Associated Pain	May. 08	CI
Tiumbio Co., Ltd. Submits CTA for Phase 1B Clinical Trial of TU7710, A Long-Acting Recombinant Activated Factor VII, in Hemophilia A or B Patients	Mar. 26	CI
TiumBio Co., Ltd. Announces to Initiate Phase 2 Trial of TU2218 for Cancer	Mar. 11	CI
TiumBio Co., Ltd. announced that it has received KRW 19.9999947 billion in funding from SK Chemicals Co.,Ltd	Dec. 27	CI
TiumBio Co., Ltd. announced that it expects to receive funding from SK Chemicals Co.,Ltd	Dec. 19	CI
TiumBio Co., Ltd. announced that it has received KRW 18.5 billion in funding from a group of investors	23-10-22	CI
TiumBio Co., Ltd.(KOSDAQ:A321550) dropped from S&P Global BMI Index	23-09-18	CI
TiumBio Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-21	CI
Hansoh Pharmaceutical Group Company Limited Announces Licensing Agreement with Tiumbio Co., Ltd	22-08-08	CI
Oncodesign and TiumBio Sign Collaboration Agreement for R&D of Fibrosis Drug Candidates	21-10-21	CI
Protium Science announced that it has received KRW 6 billion in funding from TiumBio Co., Ltd.	21-09-26	CI
Protium Science announced that it expects to receive KRW 6 billion in funding from TiumBio Co., Ltd.	21-09-14	CI
TiumBio Co., Ltd. announced that it has received KRW 49.99982815 billion in funding from Hanyang Securities Co. Ltd., EBEST Investment & Securities Co., Ltd. and other investors	21-09-02	CI
TiumBio Co., Ltd. announced that it has received KRW 25 billion in funding	21-08-30	CI
TiumBio Co., Ltd. announced that it expects to receive KRW 49.99982815 billion in funding from Hanyang Securities Co. Ltd., EBEST Investment & Securities Co., Ltd. and other investors	21-08-26	CI
SK Plasma Co., Ltd. announced that it expects to receive KRW 110.00001 billion in funding from SK Discovery Co., Ltd., TiumBio Co., Ltd., and another investor	21-07-27	CI
TiumBio Co., Ltd.(KOSDAQ:A321550) added to S&P Global BMI Index	20-06-22	CI
TiumBio Co. Ltd. has completed an IPO in the amount of KRW 30 billion.	19-11-21	CI
TiumBio Co. Ltd. has filed an IPO.	19-06-24	CI

TiumBio Co., Ltd. is a Korea-based company principally engaged in the research and development of biopharmaceuticals. The Company researches and develops small molecule drugs including endometriosis treatments, uterine fibroids treatments, cancer immunotherapy drugs; and new biopharmaceuticals including hemophilia treatments, and others.

Sector

Biotechnology & Medical Research

Calendar

2024-08-12 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
TIUMBIO CO., LTD.	-30.71%	127M
REGENERON PHARMACEUTICALS, INC.	+11.60%	106B
BIONTECH SE	-4.68%	24.28B
ARGENX SE	-0.82%	21.96B
GENMAB A/S	-10.12%	18.16B
WUXI APPTEC CO., LTD.	-42.12%	16.37B
BEIGENE, LTD.	-17.47%	15.56B
NEUROCRINE BIOSCIENCES, INC.	+2.77%	13.63B
SAREPTA THERAPEUTICS, INC.	+34.58%	12.27B
INSMED INCORPORATED	+77.64%	8.87B